Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Francesca Bello, Samer Muhsen, Haider Sabhan, Alexandra Borin, Fredrik Johansson, Charlotte Höög, Ole Forsberg, Christina Wennerström, Charlotte Söderman, Mikael Lördal, Sven Almer
BACKGROUND: Ustekinumab is used to treat inflammatory bowel disease mainly in patients failing anti-tumour necrosis factor (TNF)-agents. OBJECTIVES: To provide real-world data in unselected patients with Crohn's disease (CD), treated with ustekinumab. DESIGN: Longitudinal retrospective study at four hospitals in Stockholm, Sweden. METHODS: Disease activity (Harvey-Bradshaw index and physician global assessment), laboratory parameters, endoscopic findings and drug persistence were assessed...
2024: Therapeutic Advances in Gastroenterology
#2
REVIEW
Tsz Hong Yiu, Yanna Ko, Aviv Pudipeddi, Patrizia Natale, Rupert W Leong
BACKGROUND: The expanding options in advanced therapies for ulcerative colitis (UC) and Crohn's disease (CD) present challenges in treatment selection. Persistence analysis assesses drug durability in real-world settings, acting as a surrogate marker for medication efficacy and tolerance. Unlike traditional comparative studies, persistence analysis provides insights extending beyond the initial year of treatment. AIM: To provide real-world evidence on treatment effectiveness, tolerability and preferences of physicians and patients regarding various advanced therapies for IBD...
April 23, 2024: Alimentary Pharmacology & Therapeutics
#3
JOURNAL ARTICLE
Trang L Nguyen, Alice Tew, Laura Kirton, Neil Steven
BACKGROUND: Colitis was the third most common immune-related adverse effect in melanoma patients treated with immune-checkpoint inhibitor (ICI). With the limitation of real-world data in the UK population, this study was conducted in a UK hospital where a fresh colitis guidance was introduced to evaluate the overall grading (OG) to assess colitis severity and guide the treatment. AIMS: This study aimed to investigate colitis severity by Common Terminology Criteria for Adverse Events (CTCAE) grade and overall grade at time of presentation...
April 23, 2024: Journal of Oncology Pharmacy Practice
#4
JOURNAL ARTICLE
Jun Yan He, Yang-Joon Kim, Elvira Mennillo, Iulia Rusu, Jared Bain, Arjun A Rao, Christopher Andersen, Karen Law, Hai Yang, Jessica Tsui, Alan Shen, Brittany Davidson, Divyashree Kushnoor, Yimin Shi, Frances Fan, Alexander Cheung, Li Zhang, Lawrence Fong, Alexis J Combes, Angela O Pisco, Michael G Kattah, David Y Oh
BACKGROUND: Colitis caused by checkpoint inhibitors (CPI) is frequent and is treated with empiric steroids, but CPI colitis mechanisms in steroid-experienced or refractory disease are unclear. METHODS: Using colon biopsies and blood from predominantly steroid-experienced CPI colitis patients, we performed multiplexed single-cell transcriptomics and proteomics to nominate contributing populations. RESULTS: CPI colitis biopsies showed enrichment of CD4+ resident memory (RM) T cells in addition to CD8+ RM and cytotoxic CD8+ T cells...
April 19, 2024: Journal for Immunotherapy of Cancer
#5
JOURNAL ARTICLE
Pablo Canales-Herrerias, Mathieu Uzzan, Akihiro Seki, Rafael S Czepielewski, Bram Verstockt, Alexandra E Livanos, Fiona Raso, Alexandra Dunn, Daniel Dai, Andrew Wang, Zainab Al-Taie, Jerome Martin, Thomas Laurent, Huaibin M Ko, Minami Tokuyama, Michael Tankelevich, Hadar Meringer, Francesca Cossarini, Divya Jha, Azra Krek, John D Paulsen, Matthew D Taylor, Mohammad Zuber Nakadar, Joshua Wong, Emma C Erlich, Rachel L Mintz, Emily J Onufer, Beth A Helmink, Keshav Sharma, Adam Rosenstein, Danielle Ganjian, Grace Chung, Travis Dawson, Julius Juarez, Vijay Yajnik, Andrea Cerutti, Jeremiah J Faith, Mayte Suarez-Farinas, Carmen Argmann, Francesca Petralia, Gwendalyn J Randolph, Alexandros D Polydorides, Andrea Reboldi, Jean-Frederic Colombel, Saurabh Mehandru
Vedolizumab (VDZ) is a first-line treatment in ulcerative colitis (UC) that targets the α4β7- mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1) axis. To determine the mechanisms of action of VDZ, we examined five distinct cohorts of patients with UC. A decrease in naïve B and T cells in the intestines and gut-homing (β7+ ) plasmablasts in circulation of VDZ-treated patients suggested that VDZ targets gut-associated lymphoid tissue (GALT). Anti-α4β7 blockade in wild-type and photoconvertible (KikGR) mice confirmed a loss of GALT size and cellularity because of impaired cellular entry...
April 19, 2024: Science Immunology
#6
JOURNAL ARTICLE
N Lamichhane, N Melas, V Bergqvist, N-P Ekholm, O Olén, J F Ludvigsson, H Hjortswang, J Marsal, C Eriksson, J Halfvarson
BACKGROUND: Real-world data on starting intravenous (IV) vedolizumab (VDZ) and transitioning to subcutaneous (SC) treatment in inflammatory bowel disease (IBD) are scarce. AIMS: To assess treatment outcomes of patients with IBD starting IV VDZ and switching to SC VDZ in routine clinical care. METHODS: Adult patients with IBD switching from IV to SC VDZ treatment between 1 March 2020 and 31 December 2021 were identified from the Swedish IBD quality register...
April 18, 2024: Digestive Diseases and Sciences
#7
JOURNAL ARTICLE
Katja Tepeš, Jurij Hanžel, David Štubljar, Karin Strmšek, Luka Erjavec, Eva Supovec, Zala Jagodic, Mirjam Končan, Jan Grosek, Jurij Aleš Košir, Aleš Tomažič, Urška Kogovšek, Gregor Norčič, Renata Šibli, Marija Žnidaršič, Tadeja Pačnik Vižintin, Barbara Sodin, Janez Breznik, Vanesa Anderle Hribar, Andreja Ocepek, Cvetka Pernat Drobež, Nejc Bukovnik, Andrej Zafošnik, Tamara Marušič, Nataša Jurečič Brglez, Maja Denkovski, Nataša Smrekar, Gregor Novak, Matic Koželj, Tina Kurent, Jože Simonič, Špela Pintar, Borut Štabuc, David Drobne
BACKGROUND: With the increasing number of inflammatory bowel disease (IBD) patients, it is difficult to manage them within specialised IBD teams in academic medical centres: many are therefore treated in nonacademic IBD centres. It is unclear whether the time to introducing biologics is the same in both settings. AIM: We aimed to compare treatment approach with biologics in academic vs. nonacademic centres. METHODS: We analysed Slovenian national IBD registry data (UR-CARE Registry, supported by the European Crohn's and Colitis Organisation), which included 2 academic (2319 patients) and 4 nonacademic IBD (429 patients) centres...
April 2, 2024: European Journal of Gastroenterology & Hepatology
#8
Arteen Arzivian, Eva Zhang, Robyn Laube, Rupert Leong
Tofacitinib is contraindicated in pregnancy. We present a patient with ulcerative colitis on tofacitinib who had an unplanned pregnancy. Tofacitinib was ceased, switched to vedolizumab, and she gave birth to a healthy newborn at term. Case reports of reassuring outcomes provide real-world data that assists decision-making for future patients.
April 2024: Clinical Case Reports
#9
JOURNAL ARTICLE
Kyuwon Kim, Jae Jun Park, Hyuk Yoon, Jun Lee, Kyeong Ok Kim, Eun Sun Kim, Su Young Kim, Sun-Jin Boo, Yunho Jung, Jun Hwan Yoo, Sung Wook Hwang, Sang Hyoung Park, Suk-Kyun Yang, Byong Duk Ye
BACKGROUND/AIM: We aimed to validate clinical decision support tools (CDSTs) to predict real-life effectiveness of vedolizumab (VDZ) in patients with inflammatory bowel disease. METHODS: We retrospectively enrolled patients with Crohn's disease (CD) or ulcerative colitis (UC) treated with VDZ at 10 tertiary referral centres in Korea between January 2017 and November 2021. We assessed clinical remission (CREM) and response (CRES), corticosteroid-free clinical remission (CSF-CREM) and response (CSF-CRES), biochemical response based on C-reactive protein (BioRES[CRP]) and faecal calprotectin (BioRES[FC]), endoscopic healing (EH), and the need to optimise or switch drugs based on CDST-defined response groups...
April 14, 2024: Alimentary Pharmacology & Therapeutics
#10
REVIEW
Javier Plaza, Alejandro Mínguez, Guillermo Bastida, Remedios Marqués, Pilar Nos, Jose Luis Poveda, Inés Moret-Tatay
Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the digestive tract usually characterized by diarrhea, rectal bleeding, and abdominal pain. IBD includes Crohn's disease and ulcerative colitis as the main entities. IBD is a debilitating condition that can lead to life-threatening complications, involving possible malignancy and surgery. The available therapies aim to achieve long-term remission and prevent disease progression. Biologics are bioengineered therapeutic drugs that mainly target proteins...
March 27, 2024: International Journal of Molecular Sciences
#11
REVIEW
Johann Paulo Guzman, Mohamed Maklad, Mohammed Osman, Ayat Elsherif, Masato Fujiki
Intestinal allografts are the most immunologically complex and carry the highest risk of rejection among solid organ transplantation, necessitating complex immunosuppressive management. We evaluated the latest information regarding induction immunosuppression, with an emphasis on established, novel, and emergent therapies. We also reviewed classic and novel induction immunosuppression strategies for highly sensitized recipients. Comparable progress has been made in intestinal transplantation clinical outcomes since the implementation of induction strategies...
April 9, 2024: Human Immunology
#12
JOURNAL ARTICLE
Mohammed Ansari, Kerri Glassner, Malcolm Irani, Adam Saleh, Lin Wang, Chika Ezeana, Stephen Wong, Caroline Perry, Bincy Abraham
OBJECTIVE: We aimed to investigate whether vedolizumab (VDZ) levels were associated with inflammatory markers or clinical or endoscopic scoring in inflammatory bowel disease (IBD). METHODS: Besides demographic data, clinical scoring, endoscopic data, and laboratory markers of IBD patients treated with VDZ from 2015 to 2020 who had trough levels drawn on maintenance therapy were collected at baseline and at follow-up (after at least 8 weeks on VDZ therapy or after change in dose frequency)...
February 2024: Journal of Digestive Diseases
#13
JOURNAL ARTICLE
Bénédicte Caron, Alexandre Habert, Olivier Bonsack, Houda Camara, Elodie Jeanbert, Tommaso Lorenzo Parigi, Patrick Netter, Silvio Danese, Laurent Peyrin-Biroulet
BACKGROUND: Many patients with inflammatory bowel disease (IBD) have signs or symptoms of active disease despite multiple treatment attempts. This emerging concept is defined as difficult-to-treat IBD. AIM: The objective of this study was to investigate for the first time the treatment persistence, efficacy and safety of biologics or small molecules used in 4th or 5th line therapy. METHODS: We reviewed all consecutive patients with IBD treated at the Nancy University Hospital between July 2022 and April 2023 with the 4th or 5th line treatment for at least three months...
April 9, 2024: United European Gastroenterology Journal
#14
JOURNAL ARTICLE
Michael Chiorean, Jeanne Jiang, Ninfa Candela, Grace Chen, Hela Romdhani, Dominick Latremouille-Viau, Sherry Shi, Rebecca Bungay, Annie Guerin, Tao Fan
OBJECTIVE: To compare real-world treatment persistence, dose escalation, rates of opportunistic or serious infections, and healthcare costs in patients with Crohn's disease (CD) receiving vedolizumab (VDZ) vs ustekinumab (UST) in the United States. METHODS: A retrospective observational study in adults with CD initiated on VDZ or UST on/after 26 September 2016, was performed using the IBM Truven Health MarketScan databases (1 January 2009-30 September 2018). Rates of treatment persistence, dose escalation, opportunistic or serious infection-related encounters, and healthcare costs per patient per month (PPPM) were evaluated...
April 8, 2024: Current Medical Research and Opinion
#15
JOURNAL ARTICLE
Mahmoud Mosli
INTRODUCTION: Multiple therapies are currently available for inflammatory bowel disease (IBD); it is therefore crucial to understand patterns of drug change. This study aimed to examine the patterns of biological drug change and identify predictors of change in patients with IBD. METHODS: We performed a retrospective study of patients diagnosed with IBD who were initiated on treatment with biologics between June 2017 and October 2022. The study's primary objective was to describe biologic drug change patterns...
2024: Inflammatory Intestinal Diseases
#16
JOURNAL ARTICLE
Hyperbaric Oxygen Enabled a Transition to Oral Steroids in an Acute Severe Ulcerative Colitis Flare.
Megan M Hennessey, Sara R Zelman, Pam M Hannigan, Kimberly B Wilkinson, Corey A Siegel, Jay C Buckey
BACKGROUND: Ulcerative colitis (UC) is characterized in part by a dysregulated response to tissue hypoxia. While intravenous (IV) steroids are the mainstay of treatment for acute severe UC (ASUC), up to one-third of patients are refractory to steroids alone and require rescue therapy. CASE DESCRIPTION: A 71-year-old female with extensive UC on infliximab presented with abdominal pain and more than 10 bloody bowel movements per day. Her infliximab concentration was undetectable with a positive antibody level...
April 2024: Crohn's & colitis 360
#17
J van Gendt, R Emaus, M C Visschedijk, D J Touw, D G Bouwknegt, K de Leeuw, J R Prins, P Malik, Paola Mian
BACKGROUND AND OBJECTIVE: Although little information is available on the pharmacokinetics (PK) of monoclonal antibodies (mAbs) during pregnancy, multiple mAbs are being used during pregnancy for various indications. The aim of this systematic literature review was to characterize the PK of mAbs throughout pregnancy. METHODS: A systematic literature search was carried out in PubMed and Embase on 21 April 2023. Articles were included when information on PK or exposure parameters of mAbs in pregnant women was available...
April 7, 2024: Clinical Pharmacokinetics
#18
EDITORIAL
Dahham Alsoud, Bram Verstockt, Séverine Vermeire
No abstract text is available yet for this article.
April 6, 2024: Inflammatory Bowel Diseases
#19
JOURNAL ARTICLE
Ruben Y Gabriëls, Anne M van der Waaij, Matthijs D Linssen, Michael Dobosz, Pia Volkmer, Sumreen Jalal, Dominic Robinson, Marcela A Hermoso, Marjolijn N Lub-de Hooge, Eleonora A M Festen, Gursah Kats-Ugurlu, Gerard Dijkstra, Wouter B Nagengast
OBJECTIVE: Improving patient selection and development of biological therapies such as vedolizumab in IBD requires a thorough understanding of the mechanism of action and target binding, thereby providing individualised treatment strategies. We aimed to visualise the macroscopic and microscopic distribution of intravenous injected fluorescently labelled vedolizumab, vedo-800CW, and identify its target cells using fluorescence molecular imaging (FMI). DESIGN: Forty three FMI procedures were performed, which consisted of macroscopic in vivo assessment during endoscopy, followed by macroscopic and microscopic ex vivo imaging...
April 5, 2024: Gut
#20
JOURNAL ARTICLE
Ohad Atia, Chagit Friss, Gili Focht, Ramit Magen Rimon, Natan Ledderman, Shira Greenfeld, Amir Ben-Tov, Yiska Loewenberg Weisband, Eran Matz, Yuri Gorelik, Yehuda Chowers, Iris Dotan, Dan Turner
BACKGROUND: In this nationwide study, our objective was to compare the durability of first-line biologics in ulcerative colitis (UC), categorized into monotherapy and combotherapy with immunomodulators. METHODS: We utilized data from the nationwide epi-IIRN cohort from 2005 to 2020. Durability was defined as consistent treatment without surgery. Comparisons were based on stringent propensity score-matching. RESULTS: We included 15 111 patients with UC, of whom 2322 (15%) received biologics, with a median follow-up of 7...
April 5, 2024: Inflammatory Bowel Diseases
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
